Form 4: Processa Pharmaceuticals CFO Reports Stock Transactions

James H. Stanker, CFO of Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units.

Summary

• On April 5, 2024, James H. Stanker, the CFO of Processa Pharmaceuticals, engaged in transactions involving common stock, acquiring 1,675 shares through the distribution of vested restricted shares and disposing of 518 shares at a price of $2.79.
• Following these transactions, Stanker directly owned 6,120 shares of common stock.
• On July 10, 2024, Stanker acquired 644 shares through the distribution of vested restricted shares and disposed of 282 shares at a price of $1.71, resulting in direct ownership of 6,482 shares.
• Stanker also holds multiple tranches of Restricted Stock Units (RSUs) that convert into common stock, vesting at various dates including January 1, 2025, and January 1, 2027, some contingent on performance goals.
• As of the latest report, Stanker beneficially owns 29,547 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral. It simply reports transactions.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company insiders as an indicator of management's confidence in the company's prospects.

Key Dates

Keywords

Form 4, Processa Pharmaceuticals, Stock Transactions, Restricted Stock Units, Beneficial Ownership, Insider Trading, CFO, James H. Stanker, PCSA